At 39, Mr Kai was given 3 to 6 months to live. Stage IV liver cancer. A tumour wrapped around his blood vessels. Doctors at home with no further options.
He travelled 36 hours by train to Guangzhou, China walked into Fuda Cancer Hospital, and is now 57, liver cancer free.
That is a documented case, and why patients researching liver cancer treatment in China arrive at Fuda.
Fuda treats advanced hepatocellular carcinoma (HCC) and liver metastases with minimally invasive methods that most hospitals in Southeast Asia, India, and the Middle East do not offer.
Three facts about Fuda you need to know:
- 30,000+ international patients from 100+ countries, including liver cancer cases from Indonesia, Malaysia, the Philippines, and Denmark.
- Over 50% of liver cancer patients globally are diagnosed at an advanced stage, when surgery is no longer viable. Fuda's clinical model is built for this group.
- Cryoablation for liver cancer is recommended in the NCCN guidelines (2010). HAIC is included in China's NHC guidelines for primary liver cancer (2022 edition).
My 1Health is a global medical tourism company partnered with Fuda Cancer Hospital to help international patients access specialist liver cancer care at no additional cost to the patient.
We forward your medical reports to Fuda's multidisciplinary team, coordinate the treatment plan and cost estimate, and handle visa documentation, travel logistics, and airport arrangements for free.
We take care of everything, so you can focus on getting better
Trusted by Millions Seeking World-Class Treatment
Instant visa letter
Flight bookings
Airport pickup
Accommodation
24/7 support
Share your reports now via this secure link and receive a treatment plan from Fuda's team
Why Fuda Stands Apart for Advanced Liver Cancer
Most hospitals follow a fixed protocol: surgery, chemotherapy, then palliative care. When surgery is ruled out and chemotherapy stops working, the options run out.
Fuda Cancer Hospital clinical model starts exactly where that ends.
- JCI-accredited, Jinan University affiliated. Operating as a cancer-specialist hospital in Guangzhou since 2001.
- First in China to introduce NanoKnife (irreversible electroporation). A technology that destroys tumours next to blood vessels and bile ducts without damaging surrounding tissue.
- Personalised treatment sequencing. Fuda's MDT builds a plan specific to your tumour. Interventional therapy to reduce burden, ablation to destroy residual disease, immunotherapy to trigger a systemic response.
- No pricing premium for international patients. International patients pay the same rates as Chinese citizens.
- Language support for your region. Indonesian, Malay, Arabic, Hindi, Vietnamese, Thai, Russian, and English spoken.
7 Liver Cancer Treatments Available at Fuda, Guangzhou
Every treatment below is guideline-recognised or backed by published clinical data.
Fuda's approach is to combine them in sequence, 2-3 tailored to how your tumour responds.
1. Cryoablation: freezing liver tumours without open surgery
What it is: Extreme cold delivered through thin probes directly into the tumour under CT or ultrasound guidance.
The freeze-thaw cycle ruptures cancer cells, cuts off blood supply, and destroys the tumour .
Why Fuda for cryoablation: Fuda has performed cryoablation on liver tumours since 2001.
Published data from 235 HCC patients showed 1-year, 3-year, and 5-year survival rates of 78.4%, 54.1%, and 39.8%, exceeding outcomes for resection alone in the same period.
Cryoablation is recommended in the NCCN liver cancer treatment guidelines (2010).
The immune advantage: Cryoablation triggers a systemic immune response, the dying tumour releases antigens that activate the immune system against cancer cells elsewhere.
This is why Fuda combines it with immunotherapy as a core strategy.
Speak to Fuda's team About Cryoablation
2. NanoKnife (IRE): precision ablation near blood vessels
What it is: NanoKnife (irreversible electroporation, IRE) delivers targeted electrical pulses that destroy cancer cell membranes without heat or cold.
This matters when tumours sit near the bile duct, major arteries, or the hepatic hilum, locations where standard ablation risks damaging surrounding structures.
NanoKnife destroys the tumour while leaving blood vessels, bile ducts, and nerves intact.
Why Fuda for NanoKnife: Fuda was the first hospital in China to introduce NanoKnife.
It has been used at Fuda for both primary liver cancer and liver metastases, including one case where all 3 lesions (pancreas and 2 liver metastases) were ablated in a single procedure session.
3. TACE and HAIC: targeted chemotherapy through the artery
What it is: TACE (transcatheter arterial chemoembolisation) and HAIC (hepatic arterial infusion chemotherapy) deliver chemotherapy directly into blood vessels that feed the tumour.
This concentrates the drug at the tumour site at levels systemic IV chemotherapy cannot achieve, while significantly reducing body-wide side effects.
The difference between them: TACE also injects embolic agents to cut off the tumour's blood supply simultaneously.
HAIC, specifically HAIC-FOLFOX, is used for advanced HCC with heavy tumour burden inside the liver or portal vein tumour thrombus (PVTT).
The Japanese Society of Hepatology listed HAIC as effective for locally advanced HCC in 1995. China's NHC guidelines include it in the 2022 edition.
What patients report: Uncle Wang, a colorectal liver metastasis patient who described prior interventional therapy elsewhere as 'excruciating', received HAIC at Fuda and said: 'Almost no discomfort. I could eat and sleep as usual.'
Is TACE or HAIC for My Case? Ask Fuda oncologists
4. Iodine-125 seed implantation: internal radiation for residual disease
What it is: Radioactive iodine-125 seeds are implanted directly into residual tumour tissue under image guidance.
Each seed delivers continuous low-dose radiation for several months, gradually eliminating remaining cancer cells.
Used when ablation has addressed the main lesion but active tissue remains, or when disease has spread to adjacent lymph nodes.
Real case: Uncle Wang received iodine-125 seed implantation for retroperitoneal lymph node involvement, a complication that emerged even as his liver metastases were responding to earlier treatment.
It extended disease control without additional open procedures.
5. Immunotherapy and targeted therapy combinations
What it is: Immune checkpoint inhibitors (PD-1/PD-L1 agents) and molecular targeted drugs, used as maintenance treatment and combined directly with ablation.
When cryoablation destroys tumour tissue, it releases antigens, combining this with a checkpoint inhibitor may amplify the immune response against remaining cancer cells.
Real case: Nada from Malaysia had cycled through nearly 20 immunotherapy treatments with no response.
Multiple liver metastases grew. Her abdomen swelled to the size of a 6- 7 month pregnancy.
After a combined interventional and immunotherapy approach at Fuda, her abdominal swelling eased by the fourth cycle and some metastases shrank.
6. Conversion therapy: turning inoperable into operable
What it is: When a tumour is too large or too vascular to remove safely, Fuda's team may use interventional therapy first to shrink and devascularise it, then reassess whether surgery has become viable.
Real case: Mr Kai in 2004 had a 7 to 10 cm tumour declared unresectable. After conversion therapy at Fuda, the tumour shrank enough for surgery.
A quarter of his liver was successfully removed. He lived without recurrence for 18 years.
7. Surgical resection: when the diagnosis needs correcting first
What makes Fuda different: Fuda requires a pathological report before any treatment begins. Imaging alone, including PET-CT, is not sufficient.
This rule exists because misclassification of liver tumours is more common than patients are led to believe, and a wrong diagnosis leads to the wrong treatment.
Real case: A 32-year-old Indonesian patient arrived with an HCC diagnosis from another hospital.
Fuda's radiologists suspected a different tumour type. Biopsy confirmed a low-grade vascular tumour, not HCC.
Professor Wang Jiannan performed the correct resection in just over 30 minutes. The right diagnosis changed both the procedure and the prognosis.
Real Patients, Documented Results: What We Have Seen at Fuda
These cases are drawn from Fuda's own published clinical records. They are individual outcomes
Mr Kai- Stage IV HCC. 21 years and counting.
Diagnosed in 2004 with a 7 to 10 cm liver tumour, told he had 3 to 6 months to live. Conversion therapy at Fuda shrank the tumour.
One quarter of his liver was resected. He lived without recurrence for 18 years.
In 2022, the cancer returned. Treated with TACE, arterial infusion, and cryoablation.
A second recurrence in early 2025 was met with intratumoral drug injection and super-selective arterial embolisation. At 57, he continues treatment at Fuda.
Nada- Malaysia. Liver metastases from melanoma. Multiple immunotherapy drugs had failed.
After 30+ radiotherapy sessions and nearly 20 immunotherapy treatments, multiple liver metastases appeared in early 2023.
Further immunotherapy produced no response. Her abdomen swelled to the size of a late-stage pregnancy.
She contacted Fuda through their Malaysia office. After the first interventional treatment, her condition began to improve.
By the fourth cycle, the swelling had eased, some metastases had shrunken, and there were no signs of recurrence at the original tumour site.
Uncle Wang. Colorectal liver metastasis. Chemotherapy resistant.
Sigmoid colon cancer with liver metastases in segments S4, S5, and the caudate lobe. After surgery and chemotherapy, liver masses reappeared.
By 2024, tumours had enlarged. At Fuda, Dr Pang Xiaoming's team planned HAIC to shrink the tumour, then cryoablation.
Uncle Wang's reaction after the interventional therapy at Fuda: 'Almost no discomfort. I could eat and sleep as usual.'
By April 2025, liver metastases had shrunk and were less active.
32-year-old- Indonesia. HCC diagnosis corrected.
Arrived with an HCC diagnosis from another hospital. Fuda's radiologists suspected a different tumour type.
Biopsy confirmed a vascular-type low-grade malignant tumour, not HCC. Professor Wang Jiannan performed the correct resection in just over 30 minutes.
The right diagnosis changed the procedure and the prognosis.
BENT- Denmark. Intrahepatic cholangiocarcinoma. Chemotherapy failed after six months.
Six months of chemotherapy in Denmark showed no results — two CT scans during treatment confirmed progression.
His family found Fuda. In October 2018, BENT underwent NanoKnife ablation under CT and ultrasound guidance.
Intraoperative bleeding: approximately 0.5 ml. Discharged in stable condition two weeks later.
Share your reports with My 1Health and we will forward them to Fuda's MDT for a preliminary review.
Who Is a Good Candidate for Treatment at Fuda?
Fuda assesses each case individually based on medical reports and imaging.
In our experience coordinating cases, the patients who benefit most share specific characteristics.
Cases Fuda regularly accepts:
- Primary HCC at any stage where surgical resection is not viable — tumour size, location near blood vessels, multiple lesions, or compromised liver function from cirrhosis or hepatitis
- Recurrent liver cancer after prior resection or ablation — Fuda treats recurrences as a continuing case, not a failed one
- Liver metastases from colorectal cancer, melanoma, breast cancer, or pancreatic cancer, where the primary tumour is controlled and liver disease is the main challenge
- Chemo-resistant HCC - patients who have failed systemic chemotherapy or targeted therapy
- Advanced HCC with portal vein tumour thrombus (PVTT) - HAIC is recommended for this specific presentation in Japanese, South Korean, and Chinese national guidelines
- Elderly patients and those with Child-Pugh A to B7 liver function- Fuda has documented HAIC tolerance data for this group
Cases requiring further assessment:
- Very low platelet counts (below 50 x 10 to the power of 9 per litre for cryoablation) may need a modified approach
- Severe extrahepatic metastasis where systemic treatment is the primary need rather than local ablation
- Patients seeking liver transplantation — Fuda specialises in ablation and interventional oncology, not transplantation
The only way to confirm whether your case qualifies is to submit your reports. Fuda's MDT reviews each case and provides a preliminary assessment.
How Much Does Liver Cancer Treatment Cost at Fuda? (2026)
Fuda's pricing is in Chinese Renminbi (RMB) and applies equally to Chinese and international patients.
Costs below are 2026 approximates. Your final cost depends on which treatments are used, number of cycles, and length of stay.
Exchange rate: 1 USD = 7.25 RMB .
| Treatment | Cost (RMB) 2026 | USD | Notes |
|---|---|---|---|
| Cryoablation (per session) | 30,000 to 80,000 | $4,100 to $11,000 | Technology fee. Materials separate. |
| NanoKnife / IRE (per session) | 50,000 to 100,000 | $6,900 to $13,800 | First in China to offer. |
| TACE (per cycle) | 20,000 to 50,000 | $2,750 to $6,900 | 2 to 4 cycles common. |
| HAIC (per cycle) | 25,000 to 60,000 | $3,450 to $8,300 | Min. 4 cycles if responding. |
| Iodine-125 seeds | 30,000 to 70,000 | $4,100 to $9,700 | Residual or lymph node disease. |
| Immunotherapy / targeted | 10,000 to 50,000/mo | $1,400 to $6,900/mo | Varies by drug. |
| PET-CT / MRI imaging | 7,000 to 10,000 | $970 to $1,380 | Per scan. |
| Early-stage combined (2 to 3 wks) | 80,000 to 200,000 | $11,000 to $27,600 | First admission. |
| Advanced multi-phase case | 200,000 to 400,000 | $27,600 to $55,200 | Multiple cycles. |
Included: Technology fee, inpatient bed, nursing care, standard medications, daily itemised expense summary.
Billed separately: Consumable materials (catheters, ablation needles, iodine seeds), anaesthesia, external specialist fees, traditional Chinese medicine if selected.
Context: Equivalent minimally invasive liver cancer treatment in the US typically costs $60,000 to $150,000.
Private oncology in Western Europe starts at £40,000 per admission. Fuda's cost differential is significant, and the technology is not lesser.
Fuda introduced NanoKnife to China before most hospitals in Southeast Asia had access to it.
Airport pickup and drop-off are included for patients and companions on the same flight.
For a personalised cost estimate, send your reports to My 1Health and we will request a detailed estimate from Fuda.
How to Travel to Guangzhou for Liver Cancer Treatment
Guangzhou Baiyun International Airport is one of China's highest-traffic international hubs.
For patients from Southeast Asia, South Asia, and the Middle East, it is often closer than Singapore or Bangkok.
Flight times to Guangzhou (approximate)
- Jakarta, Indonesia: 4 hours
- Kuala Lumpur, Malaysia: 3.5 hours
- Manila, Philippines: 2.5 hours
- Ho Chi Minh City, Vietnam: 2 hours
- Bangkok, Thailand: 3 hours
- Mumbai, India: 6 hours
- Dubai, UAE: 8 hours
- Dhaka, Bangladesh: 4.5 hours
Visa
Most patients from Southeast Asia, South Asia, and the Middle East require a Chinese medical or tourist visa.
Fuda's international patient team provides the hospital documentation needed for the application.
Fuda has representative offices in Malaysia and Manila that support the local process. My 1Health coordinates this documentation as part of standard coordination.
Length of stay
- Single cryoablation or TACE cycle: 3 to 7 days
- Combined HAIC and cryoablation: 2 to 4 weeks
- Multi-phase or complex cases: 3 to 6 weeks
- Subsequent cycles: patients typically return for each cycle rather than staying continuously
Language support
Fuda directly supports Indonesian, Malay, Arabic, Hindi, Vietnamese, Thai, Russian, and English-speaking patients.
My 1Health can coordinate additional interpretation support, working with the hospital's own language team.
Accommodation, culture, and religious needs
- Halal food: Available at Fuda's dining facility on the sixth floor, alongside Chinese and Southeast Asian menu options.
- Prayer facilities: My 1Health can advise on the nearest mosque to the hospital and prayer rooms available in the local area. Guangzhou has an established Muslim community and multiple mosques within a short distance of the hospital.
- Companion accommodation: Companion beds inside the hospital can be arranged for an additional fee. My 1Health coordinates hotel recommendations near Fuda for families on longer stays.
- Cultural support: Fuda's international patient team has experience with patients from Southeast Asia, South Asia, and the Middle East. Language and cultural support are part of standard coordination, not an add-on.
How My 1Health Coordinates Your Treatment at Fuda
My 1Health has assisted 54,000+ patients from 95+ countries.
We work with Fuda Cancer Hospital as a coordination partner, not a booking agent.
Our role is to make the process of getting to Fuda as clear and low-friction as possible, at no additional cost to the patient.
How it works, step by step:
- Step 1: You share your medical reports, imaging results, and diagnosis with My 1Health via WhatsApp.
- Step 2: We forward your reports securely to Fuda's specialist liver cancer multidisciplinary team.
- Step 3: Fuda's team reviews the case and sends back a tailored treatment plan and cost estimate.
- Step 4: We coordinate appointment confirmation, visa documentation, airport arrangements, accommodation, and interpretation support.
- Step 5: A dedicated patient support specialist is available 24/7 before, during, and after treatment.
Our same-price guarantee: You pay exactly what you would pay going to Fuda directly. The hospital covers the coordination fee.
We can also arrange a video consultation with a Fuda specialist before you commit to travel, useful for confirming your case is suitable before booking flights.
Comparing Fuda with liver cancer hospitals in Turkey?
See our guide to top liver cancer treatment hospitals in Turkey. For a broader view of cancer care in China, see cancer treatment in China for international patients.
